Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism: The Pilot Study

Trial Profile

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism: The Pilot Study

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
  • Indications Venous thromboembolism
  • Focus Adverse reactions
  • Acronyms COBRRA
  • Most Recent Events

    • 05 Jan 2018 Planned End Date changed from 1 Sep 2017 to 1 Feb 2018.
    • 12 Dec 2017 Primary endpoint (Proportion of eligible patients who consent to participate in the trial) has been met as per the results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 Results assessing feasibility presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top